194 related articles for article (PubMed ID: 18449907)
1. Genetic upregulation of matriptase-2 reduces the aggressiveness of prostate cancer cells in vitro and in vivo and affects FAK and paxillin localisation.
Sanders AJ; Parr C; Martin TA; Lane J; Mason MD; Jiang WG
J Cell Physiol; 2008 Sep; 216(3):780-9. PubMed ID: 18449907
[TBL] [Abstract][Full Text] [Related]
2. Genetic reduction of matriptase-1 expression is associated with a reduction in the aggressive phenotype of prostate cancer cells in vitro and in vivo.
Sanders AJ; Parr C; Davies G; Martin TA; Lane J; Mason MD; Jiang WG
J Exp Ther Oncol; 2006; 6(1):39-48. PubMed ID: 17228523
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation of matriptase by overexpression of bikunin attenuates cell invasion in prostate carcinoma cells.
Tsui KH; Chang PL; Feng TH; Chung LC; Hsu SY; Juang HH
Anticancer Res; 2008; 28(4A):1977-83. PubMed ID: 18649735
[TBL] [Abstract][Full Text] [Related]
4. The influence of CD44v3-v10 on adhesion, invasion and MMP-14 expression in prostate cancer cells.
Harrison GM; Davies G; Martin TA; Mason MD; Jiang WG
Oncol Rep; 2006 Jan; 15(1):199-206. PubMed ID: 16328056
[TBL] [Abstract][Full Text] [Related]
5. Evaluating the function of matriptase and N-acetylglucosaminyltransferase V in prostate cancer metastasis.
Tsui KH; Chang PL; Feng TH; Chung LC; Sung HC; Juang HH
Anticancer Res; 2008; 28(4A):1993-9. PubMed ID: 18649738
[TBL] [Abstract][Full Text] [Related]
6. The influence of matriptase-2 on prostate cancer in vitro: a possible role for β-catenin.
Webb SL; Sanders AJ; Mason MD; Jiang WG
Oncol Rep; 2012 Oct; 28(4):1491-7. PubMed ID: 22858929
[TBL] [Abstract][Full Text] [Related]
7. Active lysyl oxidase (LOX) correlates with focal adhesion kinase (FAK)/paxillin activation and migration in invasive astrocytes.
Laczko R; Szauter KM; Jansen MK; Hollosi P; Muranyi M; Molnar J; Fong KS; Hinek A; Csiszar K
Neuropathol Appl Neurobiol; 2007 Dec; 33(6):631-43. PubMed ID: 17931358
[TBL] [Abstract][Full Text] [Related]
8. Endogenous bone morphogenetic protein-7 controls the motility of prostate cancer cells through regulation of bone morphogenetic protein antagonists.
Ye L; Lewis-Russell JM; Kynaston H; Jiang WG
J Urol; 2007 Sep; 178(3 Pt 1):1086-91. PubMed ID: 17644136
[TBL] [Abstract][Full Text] [Related]
9. Morphological changes and molecular expressions of hepatocellular carcinoma cells in three-dimensional culture model.
Wu YM; Tang J; Zhao P; Chen ZN; Jiang JL
Exp Mol Pathol; 2009 Oct; 87(2):133-40. PubMed ID: 19615356
[TBL] [Abstract][Full Text] [Related]
10. In vitro inhibition of matriptase prevents invasive growth of cell lines of prostate and colon carcinoma.
Förbs D; Thiel S; Stella MC; Stürzebecher A; Schweinitz A; Steinmetzer T; Stürzebecher J; Uhland K
Int J Oncol; 2005 Oct; 27(4):1061-70. PubMed ID: 16142324
[TBL] [Abstract][Full Text] [Related]
11. Targeting the HGF/SF receptor c-met using a hammerhead ribozyme transgene reduces in vitro invasion and migration in prostate cancer cells.
Davies G; Watkins G; Mason MD; Jiang WG
Prostate; 2004 Sep; 60(4):317-24. PubMed ID: 15264243
[TBL] [Abstract][Full Text] [Related]
12. Tumor growth inhibition by synthetic and expressed siRNA targeting focal adhesion kinase.
Tsutsumi K; Kasaoka T; Park HM; Nishiyama H; Nakajima M; Honda T
Int J Oncol; 2008 Jul; 33(1):215-24. PubMed ID: 18575768
[TBL] [Abstract][Full Text] [Related]
13. Secreted LOXL2 is a novel therapeutic target that promotes gastric cancer metastasis via the Src/FAK pathway.
Peng L; Ran YL; Hu H; Yu L; Liu Q; Zhou Z; Sun YM; Sun LC; Pan J; Sun LX; Zhao P; Yang ZH
Carcinogenesis; 2009 Oct; 30(10):1660-9. PubMed ID: 19625348
[TBL] [Abstract][Full Text] [Related]
14. A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1.
Saleem M; Adhami VM; Zhong W; Longley BJ; Lin CY; Dickson RB; Reagan-Shaw S; Jarrard DF; Mukhtar H
Cancer Epidemiol Biomarkers Prev; 2006 Feb; 15(2):217-27. PubMed ID: 16492908
[TBL] [Abstract][Full Text] [Related]
15. Curcumin-targeting pericellular serine protease matriptase role in suppression of prostate cancer cell invasion, tumor growth, and metastasis.
Cheng TS; Chen WC; Lin YY; Tsai CH; Liao CI; Shyu HY; Ko CJ; Tzeng SF; Huang CY; Yang PC; Hsiao PW; Lee MS
Cancer Prev Res (Phila); 2013 May; 6(5):495-505. PubMed ID: 23466486
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of prostasin serine protease: a potential invasion suppressor in prostate cancer.
Chen LM; Hodge GB; Guarda LA; Welch JL; Greenberg NM; Chai KX
Prostate; 2001 Jul; 48(2):93-103. PubMed ID: 11433419
[TBL] [Abstract][Full Text] [Related]
17. ErbB-4 may control behavior of prostate cancer cells and serve as a target for molecular therapy.
Ben-Yosef R; Starr A; Karaush V; Loew V; Lev-Ari S; Barnea I; Lidawi G; Shtabsky A; Greif Y; Yarden Y; Vexler A
Prostate; 2007 Jun; 67(8):871-80. PubMed ID: 17440944
[TBL] [Abstract][Full Text] [Related]
18. Focal adhesion kinase: important to prostaglandin E2-mediated adhesion, migration and invasion in hepatocellular carcinoma cells.
Bai XM; Zhang W; Liu NB; Jiang H; Lou KX; Peng T; Ma J; Zhang L; Zhang H; Leng J
Oncol Rep; 2009 Jan; 21(1):129-36. PubMed ID: 19082453
[TBL] [Abstract][Full Text] [Related]
19. CVS-3983, a selective matriptase inhibitor, suppresses the growth of androgen independent prostate tumor xenografts.
Galkin AV; Mullen L; Fox WD; Brown J; Duncan D; Moreno O; Madison EL; Agus DB
Prostate; 2004 Nov; 61(3):228-35. PubMed ID: 15368474
[TBL] [Abstract][Full Text] [Related]
20. Focal adhesion kinase: a potential target in cancer therapy.
van Nimwegen MJ; van de Water B
Biochem Pharmacol; 2007 Mar; 73(5):597-609. PubMed ID: 16997283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
